title: [Memantine].
abstract: Alzheimer's disease (AD) is the most common form of dementia in Western countries. The benefits presently observed with the approved treatments are mainly symptomatic without clear evidence of neuroprotection. N-methyl-D-aspartate (NMDA) receptor antagonists have very extensive therapeutic potential in several central nervous system disorders and can be used as neuroprotective treatment in chronic neurodegenerative diseases and as symptomatic treatment in other neurologic diseases as epilepsy. Memantine, an antagonist of the glutamatergic NMDA receptor, has been recently approved for the treatment of advanced AD. Due to its action mechanism, memantine is considered a neuroprotective drug, whose utility has been demonstrated in preclinical studies, and a useful symptomatic treatment for AD and vascular dementia. We will review both aspects as well as the basic mechanisms mediating glutamatergic neurodegeneration and the implication of glutamate in cognition.
authors.affiliation: Unidad de Memoria-Alzheimer Servicio de Neurología-ICMSN Hospital Clinic i Universitari, Barcelona, Spain. jlmoli@clinic.ub.es
authors.forename: J L
authors.initials: JL
authors.lastname: Molinuevo
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects*; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D008559:Memantine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D000978:Antiparkinson Agents; D018698:Glutamic Acid; D008559:Memantine